Stock market today: Stocks fall as investors rotate out of tech into Jackson Hole
Sean Maduck, President of Corcept Endocrinology, executed a series of stock transactions involving Corcept Therapeutics Inc. (NASDAQ:CORT) on March 31 and April 1, 2025. Maduck sold a total of 100,000 shares over these two days, resulting in a combined sale value of approximately $10.1 million. The sale prices ranged from $100.00 to $114.71 per share. The transactions come amid CORT’s remarkable performance, with the stock surging 226% over the past year and 47% in the last week alone. The company’s market capitalization now stands at $8.86 billion.
In addition to these sales, Maduck also exercised options to acquire 100,590 shares, with prices ranging from $5.05 to $8.27 per share, amounting to a total transaction value of $829,979. Following these transactions, Maduck directly owns 85,622 shares of Corcept Therapeutics. These transactions were conducted under a pre-established 10b5-1 trading plan. With a "GREAT" financial health score on InvestingPro and analyst price targets ranging from $128 to $150, investors seeking deeper insights can access comprehensive analysis and 16 additional ProTips through the platform’s detailed research reports.
In other recent news, Corcept Therapeutics has announced positive results from its Phase 3 ROSELLA trial, which evaluated relacorilant in combination with nab-paclitaxel for treating platinum-resistant ovarian cancer. The study met its primary endpoint, showing a median progression-free survival (PFS) of 6.5 months compared to 5.5 months for the control group, and a median overall survival (OS) of 16.0 months versus 11.5 months. Following these results, Corcept plans to submit a New Drug Application (NDA) in the third quarter of 2025, with potential approval and market launch anticipated around 2026/27. Analysts at Truist Securities and H.C. Wainwright have both raised their price targets for Corcept Therapeutics to $150, maintaining a Buy rating on the stock.
Truist Securities highlighted the long-term durability of Corcept’s intellectual property, extending into the 2040s, as a reason for their positive outlook. Meanwhile, Corcept is also preparing for the FDA’s decision on its NDA for relacorilant, intended for treating endogenous hypercortisolism, with a target action date set for December 30, 2025. The NDA submission is supported by data from the GRACE and GRADIENT trials, which showed improvements in symptoms and a favorable safety profile. Corcept’s relacorilant has been granted orphan drug designation for hypercortisolism and ovarian cancer, reflecting its potential significance in these areas. These developments underscore Corcept’s ongoing efforts to expand the therapeutic applications of relacorilant across different conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.